All Relations between Alzheimer Disease and cannabinoids

Reference Sentence Publish Date Extraction Date Species
Alberto Llorente-Ovejero, Iker Bengoetxea de Tena, Jonatan Mart\\xc3\\xadnez-Gardeazabal, Marta Moreno-Rodr\\xc3\\xadguez, Laura Lombardero, Iv\\xc3\\xa1n Manuel, Rafael Rodr\\xc3\\xadguez-Puerta. Cannabinoid Receptors and Glial Response Following a Basal Forebrain Cholinergic Lesion. ACS pharmacology & translational science vol 5 issue 9 2022 36110372 the endocannabinoid system modulates learning, memory, and neuroinflammatory processes, playing a key role in neurodegeneration, including alzheimer's disease (ad). 2022-09-16 2022-09-20 Not clear
Ana Carolina Ruver-Martins, Ma\\xc3\\xadra Assun\\xc3\\xa7\\xc3\\xa3o Bicca, Fabiano Soares de Araujo, Beatriz Helena Lameiro de Noronha Sales Maia, Fabr\\xc3\\xadcio Alano Pamplona, Elton Gomes da Silva, Francisney Pinto Nasciment. Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer's disease symptoms: a case report. Journal of medical case reports vol 16 issue 1 2022 35820856 cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic alzheimer's disease symptoms: a case report. 2022-07-12 2022-07-19 Not clear
Yolanda Paes-Colli, Andrey F L Aguiar, Alinny Rosendo Isaac, Bruna K Ferreira, Raquel Maria P Campos, Priscila Martins Pinheiro Trindade, Ricardo Augusto de Melo Reis, Luzia S Sampai. Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice. Frontiers in cellular neuroscience vol 16 issue 2022 35707521 in clinical practice, cannabis products have already been introduced to treatment regimens of alzheimer's disease, parkinson's disease and multiple sclerosis's patients, and the mechanisms of action behind the reported improvement in the clinical outcome and disease progression are associated with their anti-inflammatory, immunosuppressive, antioxidant, and neuroprotective properties, due to the modulation of the endocannabinoid system. 2022-06-16 2022-06-20 Not clear
Yolanda Paes-Colli, Andrey F L Aguiar, Alinny Rosendo Isaac, Bruna K Ferreira, Raquel Maria P Campos, Priscila Martins Pinheiro Trindade, Ricardo Augusto de Melo Reis, Luzia S Sampai. Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice. Frontiers in cellular neuroscience vol 16 issue 2022 35707521 in this review, we describe the role played by the endocannabinoid system in the physiopathology of alzheimer, parkinson, and multiple sclerosis, mainly at the neuroimmunological level. 2022-06-16 2022-06-20 Not clear
Cl\\xc3\\xa9mence Lacroix, Isabelle Alleman-Brimault, Arnaud Zalta, Frank Rouby, Catherine Cass\\xc3\\xa9-Perrot, Elisabeth Jouve, Laurence Attolini, Romain Guilhaumou, Jo\\xc3\\xablle Micallef, Olivier Bli. What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps? Frontiers in pharmacology vol 13 issue 2022 35571129 as we know that the endocannabinoid system is largely involved in neurological disorders, we focused on the scientific rationale of medical cannabis in three neurological disorders: amyotrophic lateral sclerosis, parkinson's disease, and alzheimer's disease through pharmacological plausibility, clinical studies, and patients' view. 2022-05-16 2022-06-13 Not clear
Fenqin Chen, Jun Bai, Shanshan Zhong, Rongwei Zhang, Xiaoqian Zhang, Ying Xu, Mei Zhao, Chuansheng Zhao, Zhike Zho. Molecular Signatures of Mitochondrial Complexes Involved in Alzheimer's Disease via Oxidative Phosphorylation and Retrograde Endocannabinoid Signaling Pathways. Oxidative medicine and cellular longevity vol 2022 issue 2022 35432724 molecular signatures of mitochondrial complexes involved in alzheimer's disease via oxidative phosphorylation and retrograde endocannabinoid signaling pathways. 2022-04-18 2022-04-19 Not clear
Emine Petekkaya, Berna Ku\\xc5\\x9f, Serdar Do\\xc4\\x9fan, Hanifi Bayaro\\xc4\\x9fullar\\xc4\\xb1, Turay Mutlu, \\xc4\\xb0smet Murat Melek, Abdullah Arpac\\xc4\\xb. Possible role of endocannabinoids in olfactory and taste dysfunctions in Alzheimer's and Parkinson's patients and volumetric changes in the brain. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia vol 100 issue 2022 35398594 the purpose of this study is to determine the volumes of primary brain regions associated with smell and taste in alzheimer's and parkinson's patients and healthy controls using mr imaging and examine volumetric changes in comparison to smell/taste questionnaire and test results and endocannabinoid (ec) levels. 2022-04-10 2022-04-14 Not clear
Alexandru Vasincu, R\\xc4\\x83zvan-Nicolae Rusu, Daniela-Carmen Ababei, M\\xc4\\x83d\\xc4\\x83lina Larion, Walther Bild, Gabriela Dumitri\\xc8\\x9ba Stanciu, Carmen Solcan, Veronica Bil. Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty. Biology vol 11 issue 3 2022 35336814 the present review will explore the roles of cannabinoid receptors (cbrs) and pharmacological agents that modulate cbrs or ecs activity with reference to alzheimer's disease (ad), parkinson's disease (pd), huntington's disease (hd) and multiple sclerosis (ms). 2022-03-26 2022-04-14 Not clear
Shivanshu Bajaj, Saima Zameer, Shreshta Jain, Vaishali Yadav, Divya Vohor. Effect of the MAGL/FAAH Dual Inhibitor JZL-195 on Streptozotocin-Induced Alzheimer's Disease-like Sporadic Dementia in Mice with an Emphasis on A\\xce\\xb2, HSP-70, Neuroinflammation, and Oxidative Stress. ACS chemical neuroscience vol issue 2022 35316021 recently, pharmacological inhibition of endocannabinoid (ecb)-degrading enzymes, fatty acid amide hydrolase (faah) and monoacylglycerol lipase (magl), is being investigated to modulate the pathology of alzheimer's disease. 2022-03-22 2022-04-14 Not clear
Alessandro Papa, Silvia Pasquini, Chiara Contri, Sandra Gemma, Giuseppe Campiani, Stefania Butini, Katia Varani, Fabrizio Vincenz. Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition. Cells vol 11 issue 3 2022 35159280 the endocannabinoid system (ecs) is emerging as a particularly attractive therapeutic target in cns disorders and neurodegenerative diseases including parkinson's disease (pd), alzheimer's disease (ad), huntington's disease (hd), multiple sclerosis (ms), amyotrophic lateral sclerosis (als), stroke, traumatic brain injury (tbi), pain, and epilepsy. 2022-02-15 2022-02-17 Not clear
Chu Che. Endocannabinoid metabolism and Alzheimer's disease. Neural regeneration research vol 17 issue 9 2022 35142686 endocannabinoid metabolism and alzheimer's disease. 2022-02-10 2022-02-13 Not clear
Sai Varshini Magham, Praveen Thaggikuppe Krishnamurthy, Neenu Shaji, Lalithkumar Mani, Shivaramakrishnan Balasubramania. Cannabinoid receptor 2 selective agonists and Alzheimer's disease: An insight into the therapeutic potentials. Journal of neuroscience research vol 99 issue 11 2021 34486749 cannabinoid receptor 2 selective agonists and alzheimer's disease: an insight into the therapeutic potentials. 2022-02-04 2022-01-13 Not clear
Shuangtao Li, Yuanbing Huang, Lijun Yu, Xiaoyu Ji, Jie W. Impact of the cannabinoid system in Alzheimer's diseases. Current neuropharmacology vol issue 2022 35105293 how cannabinoids act on different endocannabinoid receptor subtypes to regulate alzheimer's disease, the roles of the endocannabinoid system in alzheimer's disease are outlined, and the underlying mechanisms are discussed. 2022-02-02 2022-02-06 Not clear
Shuangtao Li, Yuanbing Huang, Lijun Yu, Xiaoyu Ji, Jie W. Impact of the cannabinoid system in Alzheimer's diseases. Current neuropharmacology vol issue 2022 35105293 finally, we summarize the most relevant opportunities of cannabinoid pharmacology related to alzheimer's disease and discuss the potential usefulness of cannabinoids in the clinical treatment of alzheimer's disease. 2022-02-02 2022-02-06 Not clear
Deepak Kumar, Ashish Sharma, Rajeev Taliyan, Maiko T Urmera, Oscar Herrera-Calderon, Thomas Heinbockel, Shafiqur Rahman, Rohit Goya. Orchestration of the circadian clock and its association with Alzheimer's disease: Role of endocannabinoid signaling. Ageing research reviews vol 73 issue 2021 34844016 orchestration of the circadian clock and its association with alzheimer's disease: role of endocannabinoid signaling. 2022-01-27 2022-01-13 Not clear
Sai Varshini Magham, Praveen Thaggikuppe Krishnamurthy, Neenu Shaji, Lalithkumar Mani, Shivaramakrishnan Balasubramania. Cannabinoid receptor 2 selective agonists and Alzheimer's disease: An insight into the therapeutic potentials. Journal of neuroscience research vol 99 issue 11 2021 34486749 cannabinoid receptor 2 selective agonists and alzheimer's disease: an insight into the therapeutic potentials. 2021-12-11 2022-01-13 Not clear
Deepak Kumar, Ashish Sharma, Rajeev Taliyan, Maiko T Urmera, Oscar Herrera-Calderon, Thomas Heinbockel, Shafiqur Rahman, Rohit Goya. Orchestration of the circadian clock and its association with Alzheimer's disease: Role of endocannabinoid signaling. Ageing research reviews vol 73 issue 2021 34844016 orchestration of the circadian clock and its association with alzheimer's disease: role of endocannabinoid signaling. 2021-12-11 2022-01-13 Not clear
Shivanshu Bajaj, Shreshta Jain, Preeti Vyas, Sandhya Bawa, Divya Vohor. The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease? Brain research bulletin vol 174 issue 2021 34217798 the role of endocannabinoid pathway in the neuropathology of alzheimer's disease: can the inhibitors of magl and faah prove to be potential therapeutic targets against the cognitive impairment associated with alzheimer's disease? 2021-12-10 2022-01-13 Not clear
Shivanshu Bajaj, Shreshta Jain, Preeti Vyas, Sandhya Bawa, Divya Vohor. The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease? Brain research bulletin vol 174 issue 2021 34217798 anadamide (aea) and arachidonoyl glycerol (2-ag), as potential therapeutic targets with the ability to modify alzheimer's pathology by targeting the inflammatory, neurodegenerative and cognitive aspects of the disease. 2021-12-10 2022-01-13 Not clear
Hui Jing, Alex Reed, Olesya A Ulanovskaya, Jan-Sebastian Grigoleit, Dylan M Herbst, Cassandra L Henry, Haoxin Li, Sabrina Barbas, Jason Germain, Kim Masuda, Benjamin F Cravat. Phospholipase C\\xce\\xb32 regulates endocannabinoid and eicosanoid networks in innate immune cells. Proceedings of the National Academy of Sciences of the United States of America vol 118 issue 41 2021 34607960 here, we show that phospholipase c\xce\xb32 (plc\xce\xb32 or plcg2)-mutations in which are associated with autoinflammatory disorders and alzheimer's disease-serves as a principal source of diacylglycerol (dag) pools that are converted into a cascade of bioactive endocannabinoid and eicosanoid lipids by dag lipase (dagl) and monoacylglycerol lipase (mgll) enzymes in innate immune cells. 2021-12-06 2022-01-13 Not clear
Page: 
1   2   3   4   5   6   7